» Articles » PMID: 21292686

Hot Spots in Dynamic (18)FET-PET Delineate Malignant Tumor Parts Within Suspected WHO Grade II Gliomas

Overview
Journal Neuro Oncol
Specialties Neurology
Oncology
Date 2011 Feb 5
PMID 21292686
Citations 117
Authors
Affiliations
Soon will be listed here.
Abstract

Molecular imaging studies have recently found inter- and intratumoral heterogeneity in World Health Organization (WHO) grade II gliomas. A correlative analysis with tumor histology, however, is still lacking. For elucidation we conducted the current prospective study. Fifty-five adult patients with an MRI-based suspicion of a WHO grade II glioma were included. [F-18]Fluoroethyltyrosine ((18)FET) uptake kinetic studies were combined with frame-based stereotactic localization techniques and used as a guide for stepwise (1-mm steps) histopathological evaluation throughout the tumor space. In tumors with heterogeneous PET findings, the O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation status and expression of mutated protein isocitrate dehydrogenase variant R132H (IDH1) were determined inside and outside of hot spot volumes. Metabolic imaging revealed 3 subgroups: the homogeneous WHO grade II glioma group (30 patients), the homogeneous malignant glioma group (10 patients), and the heterogeneous group exhibiting both low- and high-grade characteristics at different sites (15 patients). Stepwise evaluation of 373 biopsy samples indicated a strong correlation with analyses of uptake kinetics (p < 0.0001). A homogeneous pattern of uptake kinetics was linked to homogeneous histopathological findings, whereas a heterogeneous pattern was associated with histopathological heterogeneity; hot spots exhibiting malignant glioma characteristics covered 4-44% of the entire tumor volumes. Both MGMT and IDH1 status were identical at different tumor sites and not influenced by heterogeneity. Maps of (18)FET uptake kinetics strongly correlated with histopathology in suspected grade II gliomas. Anaplastic foci can be accurately identified, and this finding has implications for prognostic evaluation and treatment planning.

Citing Articles

Predicting intraoperative 5-ALA-induced tumor fluorescence via MRI and deep learning in gliomas with radiographic lower-grade characteristics.

Suero Molina E, Azemi G, Ozdemir Z, Russo C, Krahling H, Valls Chavarria A J Neurooncol. 2024; 171(3):589-598.

PMID: 39560696 PMC: 11729117. DOI: 10.1007/s11060-024-04875-0.


Measuring the diagnostic management and follow-up imaging for glioma patients across Belgian hospitals between 2016 and 2019.

Vanhauwaert D, Vanschoenbeek K, Weyns F, Vanopdenbosch L, Tieleman A, Michotte A Cancer Med. 2024; 13(21):e70045.

PMID: 39475180 PMC: 11523142. DOI: 10.1002/cam4.70045.


Pre-operative dual-time-point [F]FET PET differentiates CDKN2A/B loss and PIK3CA mutation status in adult-type diffuse glioma: a single-center prospective study.

Lee D, Oh J, Kim J, Oh M, Oh S, Lee S Eur J Nucl Med Mol Imaging. 2024; 52(2):669-682.

PMID: 39365462 DOI: 10.1007/s00259-024-06935-z.


Automatic detection and delineation of pediatric gliomas on combined [F]FET PET and MRI.

Ladefoged C, Henriksen O, Mathiasen R, Schmiegelow K, Andersen F, Hojgaard L Front Nucl Med. 2024; 2:960820.

PMID: 39354975 PMC: 11440972. DOI: 10.3389/fnume.2022.960820.


Contribution of [F]FET PET in the Management of Gliomas, from Diagnosis to Follow-Up: A Review.

Robert J, Leclerc A, Ducloie M, Emery E, Agostini D, Vigne J Pharmaceuticals (Basel). 2024; 17(9).

PMID: 39338390 PMC: 11435125. DOI: 10.3390/ph17091228.


References
1.
Capper D, Weissert S, Balss J, Habel A, Meyer J, Jager D . Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 2009; 20(1):245-54. PMC: 8094636. DOI: 10.1111/j.1750-3639.2009.00352.x. View

2.
Popperl G, Kreth F, Herms J, Koch W, Mehrkens J, Gildehaus F . Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?. J Nucl Med. 2006; 47(3):393-403. View

3.
Heiss P, Mayer S, Herz M, Wester H, Schwaiger M, Senekowitsch-Schmidtke R . Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo. J Nucl Med. 1999; 40(8):1367-73. View

4.
Esteller M, Garcia-Foncillas J, Andion E, Goodman S, Hidalgo O, Vanaclocha V . Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000; 343(19):1350-4. DOI: 10.1056/NEJM200011093431901. View

5.
Floeth F, Pauleit D, Sabel M, Stoffels G, Reifenberger G, Riemenschneider M . Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med. 2007; 48(4):519-27. DOI: 10.2967/jnumed.106.037895. View